Literature DB >> 11830495

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells.

Yu-Tzu Tai1, Klaus Podar, Deepak Gupta, Boris Lin, Gloria Young, Masaharu Akiyama, Kenneth C Anderson.   

Abstract

It was previously demonstrated that p53 status in human multiple myeloma (MM) cells regulates distinct cell cycle responses to CD40 activation. In this study, the production of vascular endothelial growth factor (VEGF) and migration in MM cells triggered by CD40 activation was examined, and the influence of p53 status in regulating this process was determined. Two human MM cell lines that express wild-type p53 at permissive (28 degrees C) and mutant p53 at restrictive (37 degrees C) temperatures were used as a model system. CD40 activation induces a 4-fold (RPMI 8226) and a 6-fold (SV) increase in VEGF transcripts, respectively, under restrictive, but not permissive, temperatures. VEGF expression is significantly induced after CD40 activation in patient MM cells expressing mutant p53. Increased VEGF transcripts result in increased protein and secretion levels, as evidenced by immunoblotting and enzyme-linked immunosorbent assay. In a double-chamber transmigration assay, CD40 activation of MM cells induced a 3-fold (RPMI 8226) and a 5-fold (SV) increase in migration under restrictive, but not permissive, conditions. A 2- to 8-fold induction in migration of patient MM cells expressing mutant p53 was similarly observed. Transduction of MM cells with a luciferase reporter under the control of a human VEGF promoter further indicated that CD40-induced VEGF expression was mediated through a transcriptional control mechanism. Finally, adenovirus-mediated wild-type p53 overexpression down-regulated CD40-induced VEGF expression and transmigration in MM cells expressing mutant p53. These studies demonstrate that CD40 induces VEGF secretion and MM cell migration, suggesting a role for CD40 in regulating MM homing and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11830495     DOI: 10.1182/blood.v99.4.1419

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma.

Authors:  G Tsirakis; C A Pappa; F E Psarakis; M Fragioudaki; C Tsioutis; E Stavroulaki; A Boula; M G Alexandrakis
Journal:  Med Oncol       Date:  2012-03-09       Impact factor: 3.064

2.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

3.  Bone marrow angiogenesis and progression in multiple myeloma.

Authors:  Roberto Ria; Antonia Reale; Annunziata De Luisi; Arianna Ferrucci; Michele Moschetta; Angelo Vacca
Journal:  Am J Blood Res       Date:  2011-06-08

Review 4.  Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development.

Authors:  Colin Phipps; Yunxin Chen; Sathish Gopalakrishnan; Daryl Tan
Journal:  Ther Adv Hematol       Date:  2015-06

Review 5.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 6.  Targeted therapies in multiple myeloma.

Authors:  Efstathios Kastritis; Andreas Charidimou; Andreas Varkaris; Meletios A Dimopoulos
Journal:  Target Oncol       Date:  2009-01-17       Impact factor: 4.493

Review 7.  Mechanism and its regulation of tumor-induced angiogenesis.

Authors:  Manoj Kumar Gupta; Ren-Yi Qin
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

Review 8.  Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Authors:  Ivetta Danylesko; Katia Beider; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2012-05-10

9.  OspA-CD40 dyad: ligand-receptor interaction in the translocation of neuroinvasive Borrelia across the blood-brain barrier.

Authors:  Lucia Pulzova; Andrej Kovac; Rastislav Mucha; Patrik Mlynarcik; Elena Bencurova; Marian Madar; Michal Novak; Mangesh Bhide
Journal:  Sci Rep       Date:  2011-09-08       Impact factor: 4.379

10.  Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.

Authors:  Hye Won Chung; Jong-Baeck Lim
Journal:  J Transl Med       Date:  2014-04-21       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.